Analyst Price Targets — RLMD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 13, 2026 6:49 pm | Uy Ear | Mizuho Securities | $10.00 | $5.91 | StreetInsider | Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD): pullback 'a buying opprotunity' |
| January 23, 2026 11:24 am | — | Leerink Partners | $8.00 | $3.96 | TheFly | Relmada Therapeutics assumed at Outperform from Market Perform at Leerink |
| December 22, 2025 12:08 am | — | Jefferies | $9.00 | $4.35 | TheFly | Relmada Therapeutics initiated with a Buy at Jefferies |
| June 5, 2024 3:55 am | Andrea Tan | Goldman Sachs | $2.00 | $2.95 | StreetInsider | Goldman Sachs Downgrades Relmada Therapeutics Inc (RLMD) to Sell |
| October 13, 2022 3:47 pm | Andrew Tsai | Jefferies | $8.00 | $6.48 | TheFly | Relmada Therapeutics downgraded to Hold from Buy at Jefferies |
| October 13, 2022 11:55 am | Jay Olson | Oppenheimer | $7.00 | $6.75 | TheFly | Relmada downgraded to Perform at Oppenheimer after MDD monotherapy trial miss |
Latest News for RLMD
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, CPRX, TBPH, RLMD and AVTX may prove to be good additions to one's portfolio.
The mean of analysts' price targets for Relmada Therapeutics (RLMD) points to a 92.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Relmada Therapeutics (NASDAQ: RLMD - Get Free Report) and Alseres Pharmaceuticals (OTCMKTS:ALSE - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations. Insider and Institutional Ownership 45.2% of Relmada Therapeutics
Relmada Therapeutics, Inc. (RLMD) Q4 2025 Earnings Call Transcript
CORAL GABLES, Fla., March 19, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today reported audited financial results for the fourth quarter and full year ended December 31, 2025 and provided a corporate update highlighting significant progress…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RLMD.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.